[Do hematopoietic growth factors have a role in the treatment of drug-induced agranulocytosis?].

Abstract

PURPOSE:

Our study was aimed at determining the role of hematopoietic growth factor in drug-induced agranulocytosis.

METHODS:

Fifty-five cases of drug-induced agranulocytosis were reviewed and subdivided retrospectively into a G-CSF group (n = 15) and an untreated group (n = 40). Mortality and hematological recovery (number of days required for neutrophil counts to exceed 1.5 x 10(9)/L) were studied in the two groups.

RESULTS:

The mean granulocyte count was 0.09 x 10(9)/L. All patients presented infection. In the G-CSF group, no mortality (0% versus 5%, P = 0.85) and a shorter recovery time (8.1 versus 9.5 days P = 0.39) were observed. No significant difference between the two groups was observed in either the duration of antibiotic therapy (9.3 days in the G-CSF group versus 10.1 days in the untreated group, P = 0.51) or duration of hospitalization (10 days in the treated group versus 11 days in the G-CSF group, P = 0.46).

CONCLUSION:

Our results as well as a literature review indicate that G-CSF could decrease the time to hematological recovery and perhaps reduce mortality. However, the exact role of hematopoietic growth factors requires further investigations.

• Authors: E Andrès, F Maloisel, J E Kurtz, S Vinzio, J Sibilia, J L Schlienger, P Dufour
• Journal: La Revue de medecine interne (Rev Med Interne) Vol. 21 Issue 7 Pg. 580-5 (Jul 2000) ISSN: 0248-8663 [Print] France
• Vernacular Title: Les facteurs de croissance hématopoïétique ont-ils une place dans le traitement des agranulocytoses médicamenteuses?
• PMID: 10942973 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Anti-Inflammatory Agents, Non-Steroidal
• Antithyroid Agents
• Recombinant Proteins
• Granulocyte Colony-Stimulating Factor
• Filgrastim

Topics

• Aged
• Agranulocytosis (chemically induced, drug therapy)
• Anti-Bacterial Agents (adverse effects)
• Anti-Inflammatory Agents, Non-Steroidal (adverse effects)
• Antithyroid Agents (adverse effects)
• Female
• Filgrastim
• Granulocyte Colony-Stimulating Factor (therapeutic use)
• Granulocytes
• Humans
• Leukocyte Count (drug effects)
• Male
• Middle Aged
• Neutropenia (chemically induced, drug therapy)
• Recombinant Proteins
• Retrospective Studies